Quality of Life Measurement in Antidepressant Trials Is There an Added Value?

被引:25
|
作者
De Fruyt, Juergen [1 ,2 ]
Demyttenaere, Koen [2 ]
机构
[1] Gen Hosp Sint Jan AV, Dept Psychiat, BE-8000 Brugge, Belgium
[2] Univ Psychiat Ctr Leuven, Leuven, Belgium
关键词
Quality of life; Well-being; Functioning; Depressive disorder; Antidepressants; MAJOR DEPRESSIVE DISORDER; PAINFUL PHYSICAL SYMPTOMS; DOUBLE-BLIND; VENLAFAXINE XR; DULOXETINE; PLACEBO; ESCITALOPRAM; HEALTH; IMPROVEMENTS; INDIVIDUALS;
D O I
10.1159/000214442
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Quality of life (QoL) measurement in medicine has gone a long way. It has gained popularity as a more humanitarian outcome measurement. In this paper, a review is given of its historical backgrounds with a special focus on the use of QoL assessment in psychiatry. Different theoretical concepts are discussed. A closer look is taken at the use of QoL measurements in antidepressant trials. Methods: An analysis was performed on the use of QoL measurement in recent antidepressant trials of duloxetine and escitalopram. Results: QoL measurement was found to have abandoned its initial purposes, and to have been used without any theoretical framework. Conclusions: Although frequently used in antidepressant trials, the analysis and reporting of results is virtually non-existent. It remains unclear if QoL measurement, as currently used, gives any information that is not already captured by more formal depression rating scales. The question then remains whether QoL measurement in antidepressant trials has any added value and, if so, whether this is just a story of missed opportunities. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [1] Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG
    Au, Heather-Jane
    Ringash, Jolie
    Brundage, Michael
    Palmer, Michael
    Richardson, Harriet
    Meyer, Ralph M.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (02) : 119 - 128
  • [2] Assessing the Quality and Value of Quality-of-Life Measurement in Breast Cancer Clinical Trials
    Ganz, Patricia A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (03) : 196 - 199
  • [3] Communication quality and added value: a measurement instrument for municipalities
    Vos, Marita
    [J]. JOURNAL OF COMMUNICATION MANAGEMENT, 2009, 13 (04) : 362 - +
  • [4] Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?
    Fossati, R
    Confalonieri, C
    Mosconi, P
    Pistotti, V
    Apolone, G
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 87 (03) : 233 - 243
  • [5] Quality of life in randomized trials of cytotoxic or hormonal treatment of advanced breast cancer. Is there added value?
    Roldano Fossati
    Carlo Confalonieri
    Paola Mosconi
    Vanna Pistotti
    Giovanni Apolone
    [J]. Breast Cancer Research and Treatment, 2004, 87 : 233 - 243
  • [6] QUALITY OF WORK AND WORK-LIFE AS ADDED VALUE
    ACKOFF, RL
    [J]. SYSTEMS PRACTICE, 1994, 7 (05): : 485 - 486
  • [7] THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, PROGNOSIS AND QUALITY OF LIFE
    van Hout, B. A.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A4 - A5
  • [8] Problems in measurement of quality of life in dyspepsia trials
    van Zanten, SV
    [J]. EUROPEAN JOURNAL OF SURGERY, 1998, 164 : 77 - 80
  • [9] Quality of life: An additional value in cancer clinical trials?
    Kiebert, GM
    [J]. EUROPEAN CANCER NEWS, 1997, 9 (10): : 11 - 12
  • [10] MEASUREMENT OF QUALITY OF LIFE IN CLINICAL-TRIALS OF THERAPY
    FLETCHER, AE
    BULPITT, CJ
    [J]. CARDIOLOGY, 1988, 75 : 41 - 52